China SXT Pharmaceuticals (SXTC) Enterprise Value (2018 - 2026)

China SXT Pharmaceuticals (SXTC) has reported Enterprise Value for 9 consecutive years, with -$28.2 million the latest figure, recorded in Q1 2026.

• Quarterly Enterprise Value fell 55.42% year-over-year to -$28.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$28.2 million (down 55.42% YoY) and the FY2026 annual result came in at -$28.2 million, down 55.16% from the prior year.
• Enterprise Value declined to -$28.2 million in Q1 2026 per SXTC's latest filing, from -$21.2 million in the prior quarter.
• Over the last five years, Enterprise Value for SXTC reached as high as -$12.1 million in Q1 2024 and fell as low as -$28.2 million in Q1 2026.
• A 5-year average of -$18.2 million and a median of -$17.4 million in 2023 frame the typical range for Enterprise Value.
• Annual changes were most pronounced in 2024 — Enterprise Value soared 30.43% — and 2026, when it tumbled 55.42%.
• Year by year, Enterprise Value stood at -$15.6 million in 2022, then fell by 11.55% to -$17.4 million in 2023, then retreated by 6.59% to -$18.5 million in 2024, then retreated by 14.5% to -$21.2 million in 2025, then plunged by 32.92% to -$28.2 million in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered -$28.2 million, -$21.2 million, and -$18.1 million for Q1 2026, Q3 2025, and Q1 2025 respectively.